Bionano Genomics Inc.
| NASDAQ: BNGO | Healthcare / Medical Equipment & Supplies / USA |
| 1.66 | +0.0700 | +4.40% | Vol 1.27M | 1Y Perf -91.97% |
| Dec 1st, 2023 16:00 DELAYED |
| BID | 1.63 | ASK | 1.68 | ||
| Open | 1.63 | Previous Close | 1.59 | ||
| Pre-Market | - | After-Market | 1.64 | ||
| - - | -0.02 -1.20% |
| Target Price | 7.38 | Analyst Rating | Strong Buy 1.40 | |
| Potential % | 344.58 | Finscreener Ranking | ★★★★+ 57.51 | |
| Insiders Trans % 3/6/12 mo. | 100/100/100 | Value Ranking | ★★★+ 54.59 | |
| Insiders Value % 3/6/12 mo. | 100/100/100 | Growth Ranking | ★★★★+ 61.53 | |
| Insiders Shares Cnt. % 3/6/12 mo. | 100/100/100 | Income Ranking | — - | |
| Price Range Ratio 52W % | 2.16 | Earnings Rating | Neutral | |
| Market Cap | 64.47M | Earnings Date | 8th Nov 2023 | |
| Alpha | 0.03 | Standard Deviation | 0.80 | |
| Beta | 2.29 |
Today's Price Range 1.511.67 | 52W Range 1.1922.90 |
Summary:
Neutral
| Technical Indicators: | Buy |
| Moving Averages: | Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -3.64% | ||
| 1 Month | 19.55% | ||
| 3 Months | -58.70% | ||
| 6 Months | -78.28% | ||
| 1 Year | -91.97% | ||
| 3 Years | -68.45% | ||
| 5 Years | -97.73% | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -93.37 | |||
ROE last 12 Months | -37.50 | |||
ROA (5Y Avg) | -7.82 | |||
ROA last 12 Months | -34.20 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -36.45 | |||
Return on invested Capital Q | -10.90 | |||
Return on invested Capital Y | -6.56 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 2.10 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -3.60 | ||||
| 1.54 | ||||
| 23.50 | ||||
| - | ||||
| -4.70 | ||||
| -0.24 | ||||
| 2.14 | ||||
| 1.18 | ||||
| 263.71M | ||||
| Forward PE | -0.57 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 5.60 | ||||
| 6.50 | ||||
| 0.03 | ||||
| 0.04 | ||||
| -441.40 | ||||
| Leverage Ratio | 1.10 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 16.90 | ||||
| -472.30 | ||||
| -437.90 | ||||
| -324.30 | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 19.59M | ||||
| 0.07 | ||||
| 15.70 | ||||
| 13.09 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q02 2023 | -0.90 | -1.24 | -37.78 |
| Q01 2023 | -0.90 | -1.20 | -33.33 |
| Q04 2022 | -0.90 | -1.30 | -44.44 |
| Q03 2022 | -1.20 | -1.10 | 8.33 |
| Q02 2022 | -1.00 | -1.10 | -10.00 |
| Q01 2022 | -0.80 | -1.10 | -37.50 |
| Q04 2021 | -0.07 | -0.08 | -14.29 |
| Q03 2021 | -0.06 | -0.07 | -16.67 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 12/2023 QR | -0.77 | -2.67 | Negative |
| 12/2023 QR | -0.77 | 3.75 | Positive |
| 12/2023 FY | -2.18 | -190.67 | Negative |
| 12/2024 FY | -2.85 | 18.57 | Positive |
| Next Report Date | - |
| Estimated EPS Next Report | -0.75 |
| Estimates Count | 1 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 1.27M |
| Shares Outstanding | 38.84K |
| Shares Float | 37.89M |
| Trades Count | 6.47K |
| Dollar Volume | 2.02M |
| Avg. Volume | 1.22M |
| Avg. Weekly Volume | 1.49M |
| Avg. Monthly Volume | 1.25M |
| Avg. Quarterly Volume | 912.94K |
Bionano Genomics Inc. (NASDAQ: BNGO) stock closed at 1.59 per share at the end of the most recent trading day (a 0.63% change compared to the prior day closing price) with a volume of 2.46M shares and market capitalization of 64.47M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Equipment & Supplies industry, Healthcare sector and employs 405 people. Bionano Genomics Inc. CEO is R. Erik Holmlin.
The one-year performance of Bionano Genomics Inc. stock is -91.97%, while year-to-date (YTD) performance is -89.11%. BNGO stock has a five-year performance of -97.73%. Its 52-week range is between 1.19 and 22.9, which gives BNGO stock a 52-week price range ratio of 2.16%
Bionano Genomics Inc. currently has a PE ratio of -3.60, a price-to-book (PB) ratio of 1.54, a price-to-sale (PS) ratio of 23.50, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -34.20%, a ROC of -36.45% and a ROE of -37.50%. The company’s profit margin is -%, its EBITDA margin is -437.90%, and its revenue ttm is $19.59 Million , which makes it $0.07 revenue per share.
Of the last four earnings reports from Bionano Genomics Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.75 for the next earnings report. Bionano Genomics Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Bionano Genomics Inc. is Strong Buy (1.4), with a target price of $7.38, which is +344.58% compared to the current price. The earnings rating for Bionano Genomics Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Bionano Genomics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Bionano Genomics Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 26.02, ATR14 : 0.16, CCI20 : 133.66, Chaikin Money Flow : -0.17, MACD : -0.09, Money Flow Index : 61.54, ROC : 22.31, RSI : 48.77, STOCH (14,3) : 67.80, STOCH RSI : 0.81, UO : 44.97, Williams %R : -32.20), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Bionano Genomics Inc. in the last 12-months were: Mamuszka Hannah (Buy at a value of $50 000), R. Erik Holmlin (Buy at a value of $9 600)
Bionano Genomics Inc.
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
CEO: R. Erik Holmlin
Telephone: +1 858 888-7600
Address: 9540 Towne Centre Drive,Suite 100, San Diego 92121, CA, US
Number of employees: 405
